Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Cirtuvivint by Biosplice Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval
Cirtuvivint is under clinical development by Biosplice Therapeutics and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase...
Cirtuvivint by Biosplice Therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Cirtuvivint is under clinical development by Biosplice Therapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
Cirtuvivint by Biosplice Therapeutics for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Cirtuvivint is under clinical development by Biosplice Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...